I also have a better understanding now of the distribution of Phase II and Phase III trials amongst the different types of cancer ( see https://hotcopper.com.au/posts/41596009/single ).
This means that I can update the summary table.
See chart integrated into the table below - to highlight just how much Phase II and III data there is.
That's an incredible asset for a microcap biotech (MCAP $15M as at 22 November 2019), particularly given the theoretical revenue potential.
I also have a better understanding now of the distribution of...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.70 |
Change
0.090(5.59%) |
Mkt cap ! $289.5M | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.76 | $1.59 | $142.7K | 84.97K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 17175 | $1.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.77 | 6060 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |